Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

Influenza, Human Clinical Trial

Official title:

A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects ≥2 to <18 Years of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03165617
• Other study ID #: V130_12
• Secondary ID: 2016-002883-15
• Status: Completed
• Phase: Phase 3
• Start date: May 25, 2017
• Est. completion date: September 30, 2019

Study information

• Verified date: October 2020
• Source: Seqirus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 3/4, randomized, observer-blind, multi-center study, stratified study evaluated the immune (antibody) response, efficacy and safety of a cell-derived quadrivalent subunit influenza virus vaccine (Seqirus QIVc) in comparison with a non-influenza comparator, meningococcal serogroup A, C, W-135, and Y (Menveo®, GlaxoSmithKline Biologicals, S.A.) in healthy pediatric subjects ≥2 Years to <18 Years of Age

Description:

This Phase 3/4, randomized, observer-blind, multi-center, stratified study evaluated the efficacy, safety, and immunogenicity of a cell-derived quadrivalent subunit influenza virus vaccine (Seqirus QIVc) compared to a non-influenza comparator vaccine in healthy male and female participants between 2 to <18 years of age. A total of 4514 children/teens were randomized, receiving either QIVc or the non-influenza comparator vaccine. The comparator was (meningococcal [Groups A, C, W-135, and Y] oligosaccharide diphtheria CRM197 conjugate vaccine [Men ACWY]). Randomized enrollment was stratified in a 1:1 ratio via an Interactive Response Technology (IRT) system which assigned the participants into two age cohorts: 2 to <9 years of age and 9 to <18 years of age. Subjects between 2 to <9 years of age were further stratified by previous influenza vaccine status ("previously vaccinated" or "not previously vaccinated").

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4514
• Est. completion date: September 30, 2019
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years to 17 Years

Eligibility

Inclusion Criteria:

• Male or female =2 to <18 years of age on the day of the first study vaccination

• Subject's parent(s) or legal guardian(s) who was/were able to give informed consent/dissent after the nature of the study had been explained in accordance with the practices described in the study and according to local regulatory requirements

• If the subject was of an age where, according to local regulations, informed assent was required, he/she must have provided assent to participate in the study

• Subject/subject's parent(s) or legal guardian(s) was/were able to comply with study procedures and was/were available for follow-up; and

• Subject was in generally good health as per the investigator's medical judgment

Exclusion Criteria:

• Clinical signs of fever and/or an oral temperature of =100.4°F (38.0°C) within 3 days prior to vaccination;

• A known history of any anaphylaxis, serious vaccine reactions or hypersensitivity to any of the vaccine components described in the Investigator's Brochure, or had any of the contraindications listed in the package insert of the comparator vaccine;

• A history of Guillain-Barré syndrome or other de-myelinating diseases such as encephalomyelitis and transverse myelitis;

• Female subject of childbearing potential (ie, post onset of menarche and before natural or induced menopause), sexually active, and who did not use any acceptable contraceptive methods for at least 2 months prior to study entry and who did not intend to use any acceptable contraceptive methods throughout subject participation (acceptable contraceptive methods included: abstinence; hormonal contraceptive [such as oral, injection, transdermal patch, implant]; diaphragm with spermicide; tubal occlusion device; intrauterine device [IUD]; tubal ligation; male partner using condom; or male partner having been vasectomized);

• Pregnant or breast feeding female;

• Subject and/or subject's parent/guardians who were not able to comprehend or follow all required study procedures for the entire period of the study;

• Received prior Meningococcal ACWY vaccination that conflicted with national recommendations or local practices for the timing of the primary or the booster vaccination;

• Received influenza vaccination or had documented influenza disease in the last 6 months;

• Known or suspected congenital or acquired immunodeficiency; or received immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or systemic corticosteroid therapy (prednisone or equivalent) at any dose for more than 2 consecutive weeks (14 days) within the past 3 months. Topical, inhaled and intra-nasal corticosteroids were permitted. Intermittent use (1 dose in 30 days) of intra-articular corticosteroids was also permitted;

• Administration of immunoglobulin and/or any blood products within the 3 months preceding vaccination, or administration was planned during the study;

• Participated in any clinical study with another investigational product within 30 days prior to first study visit or intended to participate in another clinical study at any time during the conduct of this study. Concomitant participation in an observational study (not involving drugs, vaccines, or medical devices) was acceptable;

• Medical conditions or treatments contraindicating IM vaccination due to increased risk of bleeding. These included known bleeding disorders (such as thrombocytopenia), or treatment with anticoagulants (such as warfarin) in the 3 weeks preceding vaccination. Antiplatelet agents such as low-dose aspirin, ticlopidine (Ticlid) and clopidogrel (Plavix) were permitted;

• Evidence or history (within the previous 12 months) of drug or alcohol abuse;

• Study personnel or immediate family members (brother, sister, child, parent), the spouse of study personnel or individuals who were financially or emotionally dependent on study staff;

• Participated in this study in a prior season, if applicable; or

• Any clinical condition that, in the opinion of the investigator, may have interfered with the results of the study or pose additional risk to the subject due to participation in the study.

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• QIVc
Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
• Non-influenza Comparator Vaccine
Non-influenza comparator vaccine for intramuscular use

Locations

Country	Name	City	State
Australia	300 Murdoch Childrens Research Institute	Carlton	Victoria
Australia	302 AusTrials Pty Ltd	Sherwood	Queensland
Estonia	503 Vee Family Doctors Centre	Paide	Järvamaa
Estonia	500 Merelahe Family Doctors Centre	Tallinn	Harjumaa
Estonia	502 Medicum AS	Tallinn	Harjumaa
Estonia	504 Merekivi Family Doctors Ltd	Tallinn	Harjumaa
Estonia	505 Clinical Research Center	Tartu	Tartumaa
Estonia	505 Clinical Research Center	Tartu
Finland	607 Espoo Vaccine Research Clinic	Espoo
Finland	603 Helsinki South Vaccine Research Clinic	Helsinki
Finland	604 Helsinki South Vaccine Research Clinic	Helsinki
Finland	600 Järvenpää Vaccine Research Clinic	Järvenpää
Finland	606 Kokkola Vaccine Research Clinic	Kokkola
Finland	605 Oulu Vaccine Research Clinic	Oulu
Finland	601 Pori Vaccine Research Clinic	Pori
Finland	602 Seinäjoki Vaccine Research Clinic	Seinäjoki
Finland	608 Tampere Vaccine Research Clinic	Tampere
Finland	609 Turku Vaccine Research Clinic	Turku
Lithuania	706 Private Office of Children Pulmonologist	Alytus	Alytus Apskritis
Lithuania	700 Kaunas Silainiai Outpatient Clinic	Kaunas	Kauno Apskrits
Lithuania	702 JSC Saules seimos medicinos centras	Kaunas	Kauno Apskritis
Lithuania	703 UAB InMedica	Kaunas	Kauno Apskritis
Lithuania	704 Kauno klinikine ligonine	Kaunas	Kauno Apskritis
Lithuania	701 Naujininkai Outpatient Clinic	Vilnius	Vilnaius Apskritis
Philippines	402 De La Salle Health Sciences Institute	Dasmarinas	Cavite
Philippines	405 De La Salle Health Sciences Institute	Dasmarinas	Cavite
Philippines	403 Philippine General Hospital	Manila	National Capital Region
Philippines	404 Philippine General Hospital	Manila	National Capital Region
Philippines	400 Research Institute For Tropical Medicine	Muntinlupa	National Capital Region
Philippines	401 Research Institute For Tropical Medicine	Muntinlupa	National Capital Region
Philippines	406 Research Institute For Tropical Medicine	Muntinlupa	National Capital Region
Poland	805 Szpital Uniwersytecki nr 2 im. dr. Jana Biziela w Bydgoszczy	Bydgoszcz	Kujawsko-pomorskie
Poland	804 Prywatny Gabinet Lekarski	Debica	Podkarpackie
Poland	800 Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ) "Salmed" s. c.	Leczna	Lubelskie
Poland	NZLA Michalkowice - Jarosz i Partnerzy Spolka Lekarska	Siemianowice Slaskie	Slaskie
Poland	806 Specjalistyczny Szpital im. E. Szczeklika w Tarnowie	Tarnow	Malopolskie
Poland	803 Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy	Trzebnica	Dolnoslaskie
Spain	900 Complejo Hospitalario Universitario de Santiago	Santiago de Compostela	A Coruña
Thailand	201 ChiangMai University	Chiang Mai
Thailand	200 Srinagarind Hospital, Khon Kaen University	Khon Kaen	Muang

Sponsors (1)

Lead Sponsor	Collaborator
Seqirus

Countries where clinical trial is conducted

Australia,  Estonia,  Finland,  Lithuania,  Philippines,  Poland,  Spain,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Efficacy: First Occurrence of Either RT-PCR- or Culture-confirmed Influenza (Time-to-event Analyses) Due to Any Influenza Type A or B Strain Regardless of Antigenic Match to the Strains Selected for the Seasonal Vaccine in Subjects =2 to <18 Years	The primary efficacy endpoint was defined as the time from the last study vaccination to the onset of the first occurrence of either RT-PCR- or culture-confirmed influenza (time-to-event analyses) due to any influenza Type A or B strain regardless of antigenic match to the strains selected for the seasonal vaccine, that occurred more than 14 days after the last vaccination until the end of the influenza season.; Dataset Used: FAS-Efficacy = All subjects in the All Enrolled Set who received at least one dose of study vaccine and were evaluated for efficacy from 14 days after the last vaccination.; The success criterion used for this primary objective was as follows: The efficacy of the QIVc was demonstrated if the lower limit (LL) of the 2-sided 95% confidence interval (CI) for VE was above 20%.	Day 14 to Day 180 or until the end of the influenza season, whichever is longer
Primary	Co-Primary: First Occurrence of Either RT-PCR- or Culture-confirmed Influenza (Time-to-event Analyses) Due to Any Influenza Type A or B Strain Regardless of Antigenic Match to the Strains Selected for the Seasonal Vaccine in Subjects =3 to <18 Years	The co-primary efficacy endpoint: was defined as the time from the last study vaccination to the onset of the first occurrence of either RT-PCR- or culture-confirmed influenza (time-to-event analyses) due to any influenza Type A or B strain regardless of antigenic match to the strains selected for the seasonal vaccine, that occurred more than 14 days after the last vaccination until the end of the influenza season.Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain in subjects =3 years to <18 years of age	Day 14 to Day 180 or until the end of the influenza season, whichever is longer
Secondary	Secondary Efficacy #1: First Occurrence of Either RT-PCR- or Culture-confirmed Influenza Due to Any Influenza Type A or B Strain Regardless of Antigenic Match to the Strains Selected for the Seasonal Vaccine	The endpoint was defined as the time from the last study vaccination to the onset of the first occurrence of either RT-PCR- or culture-confirmed influenza due to any influenza Type A or B strain regardless of antigenic match to the strains selected for the seasonal vaccine, that occurred more than 14 days after the last vaccination until the end of the influenza season in subjects 2 to <18 years, 2 to <9 years, 4 to <18 years, and 9 to <18 years.; Dataset used: FAS Efficacy = All subjects in the All Enrolled Set who received at least one dose of study vaccine and were evaluated for efficacy from 14 days after the last vaccination.	Day 14 to Day 180 or until the end of the influenza season, whichever is longer.
Secondary	Secondary Efficacy #2: First Occurrence of RT-PCR-confirmed Influenza Due to Any Influenza Type A or B Strain Regardless of Antigenic Match to the Strains Selected for the Seasonal Vaccine	The endpoint was defined as the time from the last study vaccination to the onset of the first occurrence of RT-PCR-confirmed influenza due to any influenza Type A or B strain regardless of antigenic match to the strains selected for the seasonal vaccine, that occurred more than 14 days after the last vaccination until the end of the influenza season in subjects 2 to <18 years, 2 to <9 years, 4 to <18 years, and 9 to <18 years; Dataset used: FAS Efficacy - All subjects in the All Enrolled Set who received at least one dose of study vaccine and were evaluated for efficacy from 14 days after the last vaccination.	Day 14 to Day 180 or until the end of the influenza season, whichever is longer.
Secondary	Secondary Efficacy #3: First Occurrence of Culture-confirmed Influenza Due to Any Influenza Type A or B Strain Regardless of Antigenic Match to the Strains Selected for the Seasonal Vaccine	The secondary endpoint was defined as the time from the last study vaccination to the onset of the first occurrence of culture-confirmed influenza due to any influenza Type A or B strain regardless of antigenic match to the strains selected for the seasonal vaccine, that occurred more than 14 days after the last vaccination until the end of the influenza season in subjects 2 to <18 years, 2 to <9 years, 4 to <18 years, and 9 to <18 years.; Dataset used: FAS Efficacy	Day 14 to Day 180 or until the end of the influenza season, whichever is longer.
Secondary	Secondary Efficacy #4: First Occurrence of Culture-confirmed Influenza Due to Influenza Type A or B Strain Antigenically Matched to the Strains Selected for the Seasonal Vaccine	The endpoint was defined as the time from the last study vaccination to the onset of the first occurrence of culture-confirmed influenza due to influenza Type A or B strain antigenically matched to the strains selected for the seasonal vaccine, that occurred more than 14 days after the last vaccination until the end of the influenza season in subjects 2 to <18 years, 2 to <9 years, 4 to <18 years, and 9 to <18 years.	Day 14 to Day 180 or until the end of the influenza season, whichever is longer.
Secondary	Secondary Immunogenicity: Geometric Mean Titers for 4 Influenza Strains (HI Assay)	Immunogenicity was characterized by HI assay 3 weeks after the last vaccination in a subset of subjects 2 to <9 years of age enrolled in Season 2 (n=432) and Season 3 (n=319) who were immunized and had immunogenicity data at the assessed timepoints (FAS Immunogenicity). Immunogenicity was assessed at baseline (Day 1; all subjects in immunogenicity subset), at Day 22 (all "previously vaccinated" subjects receiving a single dose of the study vaccine), and at Days 29 and 50 (all "not previously vaccinated" subjects receiving 2 doses) for all 4 influenza strains using the HI assay.	Day 1 (all subjects), Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects receiving 2 doses)
Secondary	ISecondary Immunogenicity: Percentage of Subjects Achieving Seroconversion for 4 Influenza Strains (HI Assay)	Immunogenicity was characterized by HI assay 3 weeks after the last vaccination in a subset of subjects 2 to <9 years of age enrolled in Season 2 (n=432) and Season 3 (n=319) who were immunized and had immunogenicity data at the assessed timepoints (FAS Immunogenicity). Immunogenicity was assessed at baseline (Day 1; all subjects in immunogenicity subset), at Day 22 (all "previously vaccinated" subjects receiving a single dose of the study vaccine), and at Days 29 and 50 (all "not previously vaccinated" subjects receiving 2 doses) for all 4 influenza strains using the HI assay.; Seroconversion was defined as: either a prevaccination HI titer <1:10 and a postvaccination HI titer; =1:40 or a prevaccination HI titer =1:10 and a =4 fold increase in postvaccination HI titer); Dataset used: FAS Immunogenicity = All subjects in the All Enrolled Set who received at least one dose of study vaccine and provided evaluable serum samples at both baseline and after the last vaccination.	Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)
Secondary	Secondary Immunogenicity: Geometric Mean Ratio for 4 Influenza Strains (HI Assay)	Immunogenicity was characterized by HI assay 3 weeks after the last vaccination in a subset of subjects 2 to <9 years of age enrolled in Season 2 (n=432) and Season 3 (n=319) who were immunized and had immunogenicity data at the assessed timepoints (FAS Immunogenicity). Immunogenicity was assessed at baseline (Day 1; all subjects in immunogenicity subset), at Day 22 (all "previously vaccinated" subjects receiving a single dose of the study vaccine), and at Days 29 and 50 (all "not previously vaccinated" subjects receiving 2 doses) for all 4 influenza strains using the HI assay.; Geometric mean ratios (GMRs) measure the ratio in immunogenicity titers within subject\; Dataset used: FAS Immunogenicity = All subjects in the All Enrolled Set who received at least one dose of study vaccine and provided evaluable serum samples at both baseline and after the last vaccination.	Day 22/Day 1 (all previously vaccinated subjects) or Day 29/Day 1 and Day 50/Day 1 (all not previously vaccinated subjects receiving 2 doses)
Secondary	Secondary Immunogenicity: Percentage of Subjects With HI Titer =1:40 for All 4 Influenza Strains (HI Assay)	Immunogenicity was characterized by HI assay 3 weeks after the last vaccination in a subset of subjects 2 to <9 years of age enrolled in Season 2 (n=432) and Season 3 (n=319) who were immunized and had immunogenicity data at the assessed timepoints (FAS Immunogenicity). Immunogenicity was assessed at baseline (Day 1; all subjects in immunogenicity subset), at Day 22 (all "previously vaccinated" subjects receiving a single dose of the study vaccine), and at Days 29 and 50 (all "not previously vaccinated" subjects receiving 2 doses) for all 4 influenza strains using the HI assay.; The measures for assessing immunogenicity as determined by HI were as follows: Percentage of subjects with an HI titer =1:40 on Day 22 (all "previously vaccinated" subjects receiving a single vaccine dose) or Days 29 and 50 (all "not previously vaccinated" subjects receiving 2 doses) for all 4 influenza strains	Day 1 (all subjects), Day 22 (all "previously vaccinated" subjects receiving a single vaccine dose) or Days 29 and 50 (all "not previously vaccinated"subjects receiving 2 doses)
Secondary	Safety: Percentage of Subjects With Solicited Local and Systemic Adverse Events for 7 Days After Vaccination	The measures for assessing safety and tolerability were as follows: Percentage of subjects with solicited local and systemic adverse events (AEs) for 7 days after vaccination on Day 1 (for "previously vaccinated" subjects) or for 7 days after vaccination on Day 1 and Day 29 (for "not previously vaccinated" subjects) in the QIVc group and the non-influenza comparator vaccine group.; Dataset used: Solicited Safety Set	days after vaccination on Day 1 (for "previously vaccinated" subjects) or for 7 days after vaccination on Day 1 and Day 29 (for "not previously vaccinated" subjects)
Secondary	Safety: Percentage of Subjects With Unsolicited AEs for 21 Days After Vaccination	The measures for assessing safety and tolerability were as follows: Percentage of subjects with unsolicited AEs assessed from Day 1 to Day 22 (for "previously vaccinated" subjects) or from Day 1 to Day 50 (for "not previously vaccinated" subjects) in the QIVc group and the non-influenza comparator vaccine group.; Dataset used: Unsolicited Safety Set (Unsolicited Adverse Events)	Day 1 to Day 22 (for previously vaccinated subjects) or Day 1 to Day 50 (for not previously vaccinated subjects)
Secondary	Safety: Subjects With SAEs, AEs Leading to Withdrawal From Vaccination and/or the Study,(MAAEs) Within 30 Days of a 1st Occurrence, Post-ILI, and NOCDs Reported During Entire Study Participation or End of Flue Season, Whichever Was Longer	The measures for assessing safety and tolerability were as follows: Percentage of subjects with SAEs, AEs leading to withdrawal from vaccination and/or the study, Medically-Attended AEs (MAAEs) within 30 days after the first occurrence of an ILI, and New Onset of Chronic Diseases (NOCDs) reported during the subject's entire participation in the study (ie, from Day 1 to Day 181 [for "previously vaccinated" subjects] or from Day 1 to Day 209 [for "not previously vaccinated" subjects]), or until the end of influenza season, whichever was longer, and all medications associated with these events.; Dataset used: Overall Safety Set	Day 1 to Day 181 (for previously vaccinated subjects) or to Day 209 (for not previously vaccinated subjects)